Expert panelists share insight on recent updates in the management of prostate cancer presented at several key conferences.
Shared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.
Focusing on nonmetastatic castration-resistant prostate cancer, panelists review the current treatment armamentarium and shared decisionmaking.
Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.
A brief review of the value of quality of life measures while managing patients on therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC).
Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.
Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.
A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.
Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.
A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.
Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.
A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.
Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.